Dr Phadke on the Benefit of Sacituzumab Govitecan in HR+/HER2– Breast Cancer

Sneha Phadke, DO, MPH, discusses the benefit associated with treatment consisting of the antibody drug conjugates sacituzumab govitecan in hormone receptor-positive/HER2-negative breast cancer.

Related Keywords

,Holden Comprehensive Cancer Center ,Science Summit ,Breast Cancer ,Onclive Tv ,University Of Iowa Holden Comprehensive Cancer Center ,